← FDA DRUG APPROVALS

FDA ANDA · ANDA202442

LATANOPROST

Sponsor: FDC LTD

APPLICATION
ANDA202442
TYPE
ANDA
ORIGINAL APPROVAL
2016-04-22
LATEST ACTION
2023-09-22
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Prescription

Products

LATANOPROSTPrescription
LATANOPROST 0.005% · SOLUTION/DROPS · OPHTHALMIC

Approval history

2023-09-22Labeling · Supplement 11 · standardAP
2022-11-28Labeling · Supplement 9 · standardAP
2020-02-19Labeling · Supplement 7 · standardAP
2020-02-19Labeling · Supplement 6 · standardAP
2020-02-19Labeling · Supplement 2 · standardAP
2016-04-22UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →